ArticleScientific reports2025
TMEM150A overexpression was associated with poor prognosis and cancer progression in glioma verified by comprehensive analysis and cell experiments.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TMEM132A is associated with metabolic reprogramming, macrophage-oriented immune remodeling, and breast cancer progression.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transmembrane (TMEM) proteins play a pivotal role in cancer progression, with TMEM150A specifically implicated in tumorigenesis. Despite its association with cancer, the precise role of TMEM150A in glioma remains underexplored. The expression of TMEM150A in glioma and its correlation with prognosis and the immune microenvironment were systematically analyzed. Prognostic models were developed using nomograms to establish the relationship between TMEM150A expression and patient survival. Bioinformatic analyses identified pathways and networks associated with TMEM150A co-expressed genes, while in vitro assays (CCK-8, migration, and invasion assays) examined the impact of TMEM150A inhibition on glioma cell proliferation and metastasis. TMEM150A was markedly overexpressed in glioma tissues and strongly associated with clinical features such as 1p/19q codeletion, age, IDH mutation status, histological subtype, WHO grade, and poor prognosis (P < 0.05). ROC analysis revealed high diagnostic accuracy, with area under the curve values of 0.962 and 0.896 for TCGA and XENA datasets, respectively, indicating the strong diagnostic potential of TMEM150A. Overexpression of TMEM150A was identified as a risk factor for poor prognosis. The constructed nomogram demonstrated that TMEM150A expression was predictive of survival, with time-dependent AUCs for 1, 3, and 5 years exceeding 0.75, confirming its prognostic relevance. TMEM150A co-expressed genes were linked to immune responses, necrotic cell death, antigen processing and presentation, cell differentiation, mast cell activation, endothelial cell migration, wound healing, and cell proliferation. Inhibition of TMEM150A expression suppressed U251 cell growth, migration, and invasion via epithelial-mesenchymal transition (EMT). Additionally, TMEM150A expression correlated with immune scores (r = 0.585), stromal scores (r = 0.498), ESTIMATE scores (r = 0.565), macrophage infiltration (r = 0.523), aDC (r = 0.473), and neutrophil presence (r = 0.453). Overexpression of TMEM150A serves as an independent prognostic marker in glioma and is intricately linked to the tumor's immune microenvironment. Targeting TMEM150A could inhibit glioma progression through EMT modulation, presenting a potential novel therapeutic avenue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.